Discussion issues of management of pregnant women with thrombocytopenia

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The study of the pathogenesis of thrombocytopenia during pregnancy remains a very important problem, since hemostatic abnormalities continue to occupy one of the leading places among the causes of infertility, miscarriage and a large number of perinatal complications. Pregnant women with thrombocytopenia constitute a risk group for the development of bleeding events and thrombotic complications during pregnancy, in childbirth, and in the postpartum period. This article reviews literature data on the pathogenic causes of thrombocytopenia during pregnancy and on the main methods of treatment of the disease.

Full Text

Restricted Access

About the authors

Olga L. Mysik

Maternity Hospital No. 6 named after Prof. V.F. Snegiryov

Author for correspondence.
Email: olga_mysik88@mail.ru
ORCID iD: 0000-0002-8895-6845

MD

Russian Federation, Saint Petersburg

References

  1. Boehlen F, Hohlfeld P, Extermann P, et al. Platelet count at term pregnancy: A reappraisal of the threshold. Obstet Gynecol. 2000;95(1):29-33. https://doi.org/10.1016/s0029-7844(99)00537-2.
  2. Gernsheimer T, James AH, Stasi R. How I treat thrombocytopenia in pregnancy. Blood. 2013;121(1):38-47. https://doi.org/10.1182/blood-2012-08-448944.
  3. Bergmann F, Rath W. The differential diagnosis of thrombocytopenia in pregnancy. Dtsch Arztebl Int. 2015;112(47): 795-802. https://doi.org/10.3238/arztebl.2015.0795.
  4. Medscape [Internet]. Bowersox NA, Ramus RM. Тhrombocytopenia in pregnancy [cited 2016 Sept 30]. Available from: https://emedicine.medscape.com/article/272867-overview.
  5. Alarcón-Segovia D, Cabral AR. The antiphospholipid/cofactor syndromes. J Rheumatol. 1996;23(8):1319-1322.
  6. Lockshin MD. Pregnancy loss in the antiphospholipid syndrome. Thromb Haemost. 1999;82(2):641-648. https://doi.org/10.1055/s-0037-1615891.
  7. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: Report from an international working group. Blood. 2009;113(11): 2386-2393. https://doi.org/10.1182/blood-2008-07-162503.
  8. Cines DB, Levine LD. Thrombocytopenia in pregnancy. Blood. 2017;130(21):2271-2277. https://doi.org/10.1182/blood-2017-05-781971.
  9. Loustau V, Debouverie O, Canoui-Poitrine F, et al. Effect of pregnancy on the course of immune thrombocytopenia: A retrospective study of 118 pregnancies in 82 women. Br J Haematol. 2014;166(6):929-935. https://doi.org/10.1111/bjh.12976.
  10. Webert KE, Mittal R, Sigouin C, et al. A retrospective 11-year analysis of obstetric patients with idiopathic thrombocytopenic purpura. Blood. 2003;102(13):4306-4311. https://doi.org/10.1182/blood-2002-10-3317.
  11. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168-186. https://doi.org/10.1182/blood-2009-06-225565.
  12. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88(1):3-40. https://doi.org/10.1182/blood.v88. 1.3.bloodjournal8813.
  13. Chaturved Sh, McCrae KR. Thrombocytopenia in pregnancy. In: Gresele P, Kleiman NS, Lopez JA, Pag CP, eds. Platelets in thrombotic and non-thrombotic disorders. Pathophysiology, pharmacology and therapeutics: An update. London: Springer International Publishing AG; 2017. Р. 813-823. https://doi.org/10.1007/978-3-319-47462-5.
  14. Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190-4207. https://doi.org/10.1182/blood-2010-08-302984.
  15. Fogerty AE. Thrombocytopenia in pregnancy: Mechanisms and management. Transfus Med Rev. 2018;32(4):225-229. https://doi.org/10.1016/j.tmrv.2018.08.004.
  16. George JN, Davidoff F. Idiopathic thrombocytopenic purpura: Lessons from a guideline. Ann Intern Med. 1997;126(4): 317-318. https://doi.org/10.7326/0003-4819-126-4-19970 2150-00009.
  17. Lockwood CJ, Krikun G, Hausknecht V, et al. Decidual cell regulation of hemostasis during implantation and menstruation. Ann N Y Acad Sci. 1997;828:188-193. https://doi.org/10.1111/j.1749-6632.1997.tb48539.x.
  18. Петрухин В.А, Мареева М.Ю., Ковалева Л.Г., Мравян С.Р. Тромбоцитопении у беременных // Российский вестник акушера-гинеколога. – 2011. – Т. 11. – № 2. – С. 20−26. [Petrukhin VA, Mareeva MYu, Kovaleva LG, Mravyan SR. Thrombocytopenia in pregnant women. Russian bulletin of obstetrician-gynecologist. 2011;11(2):20-26. (In Russ.)]
  19. Gernsheimer T, McCrae KR. Immune thrombocytopenic purpura in pregnancy. Curr Opin Hematol. 2007;14(5):574-580. https://doi.org/10.1097/MOH.0b013e3282bf6dc2.
  20. Martí-Carvajal AJ, Peña-Martí GE, Comunián-Carrasco G. Medical treatments for idiopathic thrombocytopenic purpura during pregnancy. Cochrane Database Syst Rev. 2009;2009(4):CD007722. https://doi.org/10.1002/14651858.CD007722.pub2.
  21. Abalos E, Cuesta C, Grosso AL, et al. Global and regional estimates of preeclampsia and eclampsia: A systematic review. Eur J Obstet Gynecol Reprod Biol. 2013;170(1):1-7. https://doi.org/10.1016/j.ejogrb.2013.05.005.
  22. Ananth CV, Keyes KM, Wapner RJ. Pre-eclampsia rates in the United States, 1980-2010: Age-period-cohort analysis. BMJ. 2013;347:f6564. https://doi.org/10.1136/bmj.f6564.
  23. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins-Obstetrics. Practice Bulletin No. 166: Thrombocytopenia in pregnancy. Obstet Gynecol. 2016;128(3):e43-e53. https://doi.org/10.1097/AOG. 0000000000001641.
  24. Айламазян Э.К., Мозговая Е.В. Гестоз: теория и практика. – М.: МЕДпресс-информ, 2008. – 272 с. [Ailamazyan EK, Mozgovaya EV. Gestoz: teoriya i praktika. Moscow: MEDpress-inform; 2008. 272 р. (In Russ.)]
  25. Бикмуллина Д.Р. Молекулярно-генетические и биохимические показатели риска коагулопатического кровотечения у беременных с гестозом и его профилактика: автореф. дис. … канд. мед. наук. – СПб., 2010. – 28 с. [Bikmullina DR. Molekulyarno-geneticheskie i biokhimicheskie pokazateli riska koagulopaticheskogo krovotecheniya u beremennykh s gestozom i ego profilaktika [dissertation abstract]. Saint Petersburg; 2010. 28 р. (In Russ.)]
  26. Erez O, Mastrolia SA, Thachil J. Disseminated intravascular coagulation in pregnancy: Insights in pathophysiology, diagnosis and management. Am J Obstet Gynecol. 2015;213(4):452-463. https://doi.org/10.1016/j.ajog.2015. 03.054.
  27. Galloway S, Lyons G. Preeclampsia complicated by placental abruption, HELLP, coagulopathy and renal failure – further lessons. Int J Obstet Anesth. 2003;12(1):35-39. https://doi.org/10.1016/s0959-289x(02)00134-6.
  28. Кулаков В.И., Мурашко Л.Е., Бурлев В.А.. Клинико-биохимические аспекты патогенеза гестоза // Акушерство и гинекология. – 1995. − № 6. – С. 3−5. [Kulakov VI, Murashko LE, Burlev VA. Kliniko-biohimicheskie aspekty patogeneza gestoza. Obstetrics and gynecology. 1995;(6):3-5. (In Russ.)]
  29. Burrows RF, Hunter DJ, Andrew M, Kelton JG. A prospective study investigating the mechanism of thrombocytopenia in preeclampsia. Obstet Gynecol. 1987;70(3 Pt 1):334-338.
  30. Marumoto Y, Kaibara M, Murata T. [Hemorheological studies on platelet counts and size in normal pregnancy and pregnancies with preeclampsia and intrauterine growth retardation. (In Japanese)]. Nihon Sanka Fujinka Gakkai Zasshi. 1989;41(9):1380-1386.
  31. Tomer A. Platelet activation as a marker for in vivo prothrombotic activity: Detection by flow cytometry. J Biol Regul Homeost Agents. 2004;18(2):172-177.
  32. Салахеева Г.С., Понукалина Е.В., Глухова Т.Н., Чеснокова Н.П. Динамика изменений показателей периферической крови у беременных с гестозом различной степени тяжести // Фундаментальные исследования. – 2006. – № 10. – С. 20−23. [Salakheeva GS, Ponukalina EV, Glukhova TN, Chesnokova NP. Dinamika izmeneniy pokazateley perifericheskoy krovi u beremennykh s gestozom razlichnoy stepeni tyazhesti. Fundamental’nye issledovaniya. 2006;(10):20-23. (In Russ.)]
  33. Kharfi A, Bureau M, Giguère Y, et al. Dissociation between increased apoptosis and expression of the tumor necrosis factor-alpha system in term placental villi with preeclampsia. Clin Biochem. 2006;39(6):646-651. https://doi.org/10.1016/j.clinbiochem.2006.01.016.
  34. Mayhew TM, Ohadike C, Baker PN, et al. Stereological investigation of placental morphology in pregnancies complicated by pre-eclampsia with and without intrauterine growth restriction. Placenta. 2003;24(2-3):219-226. https://doi.org/10.1053/plac.2002.0900.
  35. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble Fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111(5):649-658. https://doi.org/10.1172/JCI17189.
  36. Rinehart BK, Terrone DA, May WL, et al. Change in platelet count predicts eventual maternal outcome with syndrome of hemolysis, elevated liver enzymes and low platelet count. J Matern Fetal Med. 2001;10(1):28-34. https://doi.org/10.1080/714052712.
  37. Kirkpatrick CA. The HELLP syndrome. Acta Clin Belg. 2010;65(2):91-97. https://doi.org/10.1179/acb.2010.020.
  38. Mao M, Chen C. Corticosteroid therapy for management of hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome: A meta-analysis. Med Sci Monit. 2015;21:3777-3783. https://doi.org/10.12659/msm.895220.
  39. Rose CH, Thigpen BD, Bofill JA, et al. Obstetric implications of antepartum corticosteroid therapy for HELLP syndrome. Obstet Gynecol. 2004;104(5 Pt 1):1011-1014. https://doi.org/10.1097/01.AOG.0000143262.85124.e8.
  40. Barrilleaux PS, Martin JN Jr, Klauser CK, et al. Postpartum intravenous dexamethasone for severely preeclamptic patients without hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome: A randomized trial. Obstet Gynecol. 2005;105(4):843-848. https://doi.org/10.1097/01.AOG.0000154887.57440.d1.
  41. Katz L, de Amorim MM, Figueiroa JN, Pinto e Silva JL. Postpartum dexamethasone for women with hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome: A double-blind, placebo-controlled, randomized clinical trial. Am J Obstet Gynecol. 2008;198(3):283.e1-283.e2838. https://doi.org/10.1016/j.ajog.2007.10.797.
  42. Макацария А.Д., Акиньшина С.В., Бицадзе В.О. Преэклампсия и HELLP-синдром как проявление тромботической микроангиопатии // Акушерство и гинекология. − 2014. − № 4. − С. 4−10. [Makatsaria AD, Akinshina SV, Bitsadze VO. Preeclampsia and hellp syndrome as a manifestation of thrombotic microangiopathy. Obstetrics and gynecology. 2014;(4):4-10. (In Russ.)]
  43. Kentouche K, Voigt A, Schleussner E, et al. Pregnancy in Upshaw-Schulman syndrome. Hamostaseologie. 2013;33(2): 144-148. https://doi.org/10.5482/HAMO-13-04-0025.
  44. Lefkou E, Hunt BJ. Bleeding disorders in pregnancy. Obst Gyn Rep Med. 2018;28(7):189-195. https://doi.org/10.1016/ j.ogrm.2018.06.002.
  45. Moatti-Cohen M, Garrec C, Wolf M, et al. Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood. 2012;119(24):5888-5897. https://doi.org/10.1182/blood- 2012-02-408914.
  46. Scully M, Thomas M, Underwood M, et al. Thrombotic thrombocytopenic purpura and pregnancy: Presentation, management, and subsequent pregnancy outcomes. Blood. 2014;124(2):211-219. https://doi.org/10.1182/blood-2014- 02-553131.
  47. Scully M. Thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome microangiopathy in pregnancy. Semin Thromb Hemost. 2016;42(7):774-779. https://doi.org/10.1055/s-0036-1587683.
  48. Saad AF, Roman J, Wyble A, Pacheco LD. Pregnancy-associated atypical hemolytic-uremic syndrome. AJP Rep. 2016;6(1):e125-e128. https://doi.org/10.1055/s-0036- 1579539.
  49. Fakhouri F, Roumenina L, Provot F, et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol. 2010;21(5):859-867. https://doi.org/10.1681/ASN.2009070706.
  50. Пархоменко Т.В. Профилактика ретромбозов в акушерстве: автореф. дис. ... канд. мед. наук. – М., 1999. – 23 с. [Parkhomenko TV. Profilaktika retrombozov v akusherstve. [dissertation]. Moscow; 1999. 23 р. (In Russ.)]
  51. Simioni P, Tormene D, Spiezia L, et al. Inherited thrombophilia and venous thromboembolism. Semin Thromb Hemost. 2006;32(7):700-708. https://doi.org/10.1055/ s-2006-951298.
  52. Blumenfeld Z, Brenner B. Thrombophilia-associated pregnancy wastage. Fertil Steril. 1999;72(5):765-774. https://doi.org/10.1016/s0015-0282(99)00360-x.
  53. Borrelli AL, Brillante M, Borzacchiello C, Berlingieri P. Hemocoagulative pathology and immunological recurrent abortion. Clin Exp Obstet Gynecol. 1997;24(1):39-40.
  54. Caruso A, De Carolis S, di Simone N. Antiphospholipid antibodies in obstetrics: New complexities and sites of action. Hum Reprod Update. 1999;5(3):267-276. https://doi.org/10.1093/humupd/5.3.267.
  55. Coumans AB, Huijgens PC, Jakobs C, et al. Haemostatic and metabolic abnormalities in women with unexplained recurrent abortion. Hum Reprod. 1999;14(1):211-214. https://doi.org/10.1093/humrep/14.1.211.
  56. Макацария А.Д., Бицадзе В.О. Антифосфолипидный синдром, генетические тромбофилии в патогенезе основных форм акушерской патологии // РМЖ (спецвыпуск). − 2006. – С. 2−10. [Makatsariya AD, Bitsadze VO. Antifosfolipidnyi sindrom, geneticheskie trombofilii v patogeneze osnovnykh form akusherskoi patologii. Russian medical journal (Spetsvypusk). 2006;2-10. (In Russ.)]
  57. Зайнулина М.С., Корнюшина Е.А., Глотов А.С., и др. Тромбофилии в акушерской практике: методические рекомендации. – 3-е изд. – СПб.: Изд-во Н-Л, 2009. – 56 с. [Zainulina MS, Kornyushina EA, Glotov AS, et al. Trombofilii v akusherskoi praktike: metodicheskie rekomendatsii. 3rd ed. Saint Petersburg: Izd-vo N-L; 2009. 56 р. (In Russ.)]
  58. Макацария А.Д., Мищенко А.Л. Вопросы циркуляторной адаптации системы гемостаза при физиологической беременности и синдром диссеминированного внутрисосудистого свертывания // Акушерство и гинекология. – 1997. − № 1. − С. 38−41. [Makatsariya AD, Mishchenko AL. Voprosy tsirkulyatornoy adaptatsii sistemy gemostaza pri fiziologicheskoy beremennosti i sindrom disseminirovannogo vnutrisosudistogo svertyvaniya. Obstetrics and gynecology. 1997;(1):38-41. (In Russ.)]
  59. Andrews EB, Marcucci G, White A, Long W. Associations between use of antenatal corticosteroids and neonatal outcomes within the Exosurf Neonatal Treatment Investigational New Drug Program. Am J Obstet Gynecol. 1995;173(1):290-295. https://doi.org/10.1016/0002-9378(95)90216-3.
  60. Макацария А.Д. Тромбофилия и беременность // Вестник Российской ассоциации акушеров-гинекологов. − 1994. − № 1. – С. 76−85. [Makatsariya AD. Trombofiliya i beremennost’. Vestnik Rossiiskoi assotsiatsii akusherov-ginekologov. 1994;(1):76-85. (In Russ.)]
  61. Falcón CR, Martinuzzo ME, Forastiero RR, et al. Pregnancy loss and autoantibodies against phospholipid-binding proteins. Obstet Gynecol. 1997;89(6):975-980. https://doi.org/ 10.1016/s0029-7844(97)00115-4.
  62. Granger KA, Farquharson RG. Obstetric outcome in antiphospholipid syndrome. Lupus. 1997;6(6):509-513. https://doi.org/10.1177/096120339700600606.
  63. Ginsberg JS, Greer I, Hirsh J. Use of antithrombotic agents during pregnancy. Chest. 2001;119(1 Suppl):122S-131S. https://doi.org/10.1378/chest.119.1_suppl.122s.
  64. Salafia CM, Cowchock FS. Placental pathology and antiphospholipid antibodies: A descriptive study. Am J Perinatol. 1997;14(8):435-441. https://doi.org/10.1055/s-2007- 994176.
  65. Кодзасова З.А. Основные принципы профилактики тромботических и геморрагических осложнений у беременных с тромбоцитопенией, обусловленной антифосфолипидным синдромом: автореф. дис. … канд. мед. наук. – М., 2006. – 25 с. [Kodzasova ZA. Osnovnye printsipy profilaktiki tromboticheskikh i gemorragicheskikh oslozhnenii u beremennykh s trombotsitopeniei, obuslovlennoi antifosfolipidnym sindromom [dissertation]. Moscow; 2006. 25 р. (In Russ.)]
  66. Гениевская М.Г., Макацария А.Д. Длительная терапия с применением фраксипарина у беременных с антифосфолипидным синдромом // Акушерство и гинекология. – 2002. − № 1. – C. 24−27. [Genievskaya MG, Makatsaria AD. Long fraxiparin therapy of pregnant women with the antiphospholipid syndrome. Obstetrics and gynecology. 2002;(1):24-27. (In Russ.)]
  67. Hirsh J, Warkentin TE, Raschke R, et al. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. 1999;115(6):1760. Chest. 1998;114(5 Suppl):489S-510S. https://doi.org/10.1378/chest.114.5_supplement.489s.
  68. Fausett MB, Vogtlander M, Lee RM, et al. Heparin-induced thrombocytopenia is rare in pregnancy. Am J Obstet Gynecol. 2001;185(1):148-152. https://doi.org/10.1067/mob.2001. 114690.
  69. Mauermann E, Vökt C, Tsakiris DA, et al. Heparin-induced thrombocytopenia in pregnancy: An interdisciplinary challenge-a case report and literature review. Int J Obstet Anesth. 2016;26:79-82. https://doi.org/10.1016/j.ijoa.2015.11.009.
  70. Elsaigh E, Thachil J, Nash MJ, et al. The use of fondaparinux in pregnancy. Br J Haematol. 2015;168(5):762-764. https://doi.org/10.1111/bjh.13147.
  71. Fesenmeier MF, Coppage KH, Lambers DS, et al. Acute fatty liver of pregnancy in 3 tertiary care centers. Am J Obstet Gynecol. 2005;192(5):1416-1419. https://doi.org/10.1016/ j.ajog.2004.12.035.
  72. Li Z, Nardi MA, Karpatkin S. Role of molecular mimicry to HIV-1 peptides in HIV-1-related immunologic thrombocytopenia. Blood. 2005;106(2):572-576. https://doi.org/ 10.1182/blood-2005-01-0243.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Mysik O.L.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 66759 от 08.08.2016 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия Эл № 77 - 6389 от 15.07.2002 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies